Key Highlights The INTerpath-001 Phase 3 study successfully achieved its primary recurrence-free survival goal in high-risk melanoma patients treated by Merck and Moderna A total of 1,137 pat
Shares of Merck experienced a remarkable surge of approximately 10% during Wednesday’s premarket session following the pharmaceutical company’s announcement alongside Moderna regarding a significant breakthrough in their collaborative personalized mRNA cancer immunotherapy program.
The companies revealed that their Phase 3 INTerpath-001 clinical study evaluating Intismeran autogene in combination with Keytruda successfully achieved both its primary objective of recurrence-free survival and secondary objective of distant metastasis-free survival among patients with fully resected Stage IIB-IV melanoma.
During premarket activity, MRK shares touched $143.52, establishing a fresh 52-week peak and surpassing the previous high watermark of $137.98.
The clinical investigation included 1,137 high-risk melanoma patients who underwent complete surgical tumor removal. Participants were administered up to nine treatment cycles of Keytruda combined with the personalized vaccine formulation, or Keytruda monotherapy, spanning roughly twelve months. The study revealed no unexpected safety concerns.
This breakthrough represents the inaugural successful late-stage clinical trial outcome for an mRNA-based cancer immunotherapy and the first investigation demonstrating superior efficacy compared to Keytruda monotherapy in this specific patient population.
These findings build upon impressive Phase 2b results disclosed in January, which demonstrated the combination therapy decreased the likelihood of disease recurrence or mortality by 49% over a five-year period when compared to Keytruda alone.
Moderna experienced explosive growth exceeding 90% during premarket trading following the announcement, with shares climbing to $118.61. The biotechnology company dominated Stocktwits trending discussions immediately after the news release.
Dean Li, Merck’s head of research and development, stated during a CNBC interview that both organizations anticipate initiating regulatory agency discussions in the coming months. Moderna’s Chief Executive Officer Stephane Bancel acknowledged that pricing strategies have not yet been determined, emphasizing that the clinical data only recently became available “within the past few days.”
Bancel further highlighted that Intismeran’s production process differs from cellular therapies as it doesn’t require harvesting patients’ own cells, potentially enabling more efficient manufacturing scalability and reduced production expenses.
Financial analysts at J.P. Morgan emphasized that the vaccine’s commercial introduction for adjuvant melanoma treatment will prove critical for Moderna’s path toward sustained profitability. Barclays’ analytical team forecasts the therapeutic approach could generate approximately $3 billion in melanoma-specific sales by 2035.
This clinical achievement follows a series of favorable analyst actions in recent weeks. Daiwa elevated MRK to Outperform from Neutral on August 17, referencing advancement across the company’s development pipeline. Wells Fargo initiated coverage with a Buy recommendation on the same date.
William Blair’s equity analyst Myles Minter commented that the interim findings establish a strong foundation for both companies to pursue regulatory authorization, and the results appear encouraging for ongoing investigations across additional cancer indications. Multiple Phase 3 trials evaluating non-small cell lung cancer applications continue patient enrollment.
The broader equity markets showed minimal movement on Wednesday, with the S&P 500 advancing just 0.1% and the Nasdaq experiencing slight declines, confirming that MRK’s substantial gains were entirely driven by company-specific catalysts.
As of Wednesday’s premarket trading session, Merck shares are currently changing hands at a new 52-week high of $143.52.
The post Merck (MRK) Stock Rockets 10% After Groundbreaking Cancer Vaccine Trial Success appeared first on Blockonomi.
